Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis

Psychosomatic Medicine

Volumn 75, Issue 1, 2013, Pages 76-82

  Burns, Michelle Nicole ^a   Nawacki, Ewa ^a   Siddique, Juned ^a   Pelletier, Daniel ^b   Mohr, David C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anxiety; clinicaltrials.gov Identifier: NCT00147446. Key words: multiple sclerosis; depression; exacerbations; illness behavior; relapsing remitting

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PREDICTION; PRIORITY JOURNAL; PSEUDOEXACERBATION; PSYCHOSOMATIC DISORDER; SECONDARY ANALYSIS; SELF REPORT; SYMPTOM CHECKLIST 90; TELECONSULTATION;

EID: 84872339945     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3182757b2b     Document Type: Article

References (38)

1. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW. Depression and multiple sclerosis. Neurology 1996;46:628-32.
2. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13:67-72.
3. Beiske AG, Svensson E, Sandanger I, Czujko B, Pedersen ED, Aarseth JH, Myhr KM. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008;15:239-45.
4. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3.
5. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674-8.
6. Uguz F, Akpinar Z, Ozkan I, Tokgoz S. Mood and anxiety disorders in patients with multiple sclerosis. Int J Psychiatr Clin Pract 2008;12:19-24.
7. Dalos NP, Rabins PV, Brooks BR, O'Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13:573-7.
8. Kroencke DC, Denney DR, Lynch SG. Depression during exacerbations in multiple sclerosis: the importance of uncertainty. Mult Scler 2001;7: 237-42.
9. McCabe MP. Mood and self-esteem of persons with multiple sclerosis following an exacerbation. J Psychosom Res 2005;59:161-6.
10. Di Legge S, Piattella MC, Pozzilli C, Pantano P, Caramia F, Pestalozza IF, Paolillo A, Lenzi GL. Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis. Mult Scler 2003;9:302-6.
11. Potagas C, Mitsonis C,Watier L, Dellatolas G, Retziou A, Mitropoulos PA, Sfagos C, Vassilopoulos D. Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. Mult Scler 2008;14:1262-8.
12. Warren S, Warren KG, Cockerill R. Emotional stress and coping in multiple sclerosis (MS) exacerbations. J Psychosom Res 1991;35:37-47.
13. Brown RF, Tennant CC, Sharrock M, Hodgkinson S, Dunn SM, Pollard JD. Relationship between stress and relapse in multiple sclerosis: part II. Direct and indirect relationships. Mult Scler 2006;12:465-75.
14. Brown RF,ValpianiEM, TennantCC,DunnSM, Sharrock M,Hodgkinson S, Pollard JD. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother 2009;82:41-56.
15. Brown RF, Tennant CC, Sharrock M, Hodgkinson S, Dunn SM, Pollard JD. Relationship between stress and relapse in multiple sclerosis: part I. Important features. Mult Scler 2006;12:453-64.
16. Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin Neurol Neurosur 1994;96:103-10.
17. Wingerchuk DM, Carter JL. Practical consultations: multiple sclerosis. Semin Neurol 2003;23:253-64.
18. GoldSM, IrwinMR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin 2009;29:309-20.
19. Sharpley CF, Bitsika V. Joining the dots: neurobiological links in a functional analysis of depression. Behav Brain Funct 2010;6:73.
20. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
21. Dantzer R, O'Connor JC, Castanon N, Lestage J, Kelley KW. Cytokines and depression: experimental evidence and intermediate mechanisms. In: Pariante CM, Nesse RM, Nutt D, Wolpert L, editors. Understanding Depression: ATranslational Approach. New York: Oxford University Press Inc.; 2009:123-38.
22. Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012;79:412-9.
23. Mohr DC. The Stress and Mood Management Program for Individuals With Multiple Sclerosis: Therapist Guide. New York: Oxford Press; 2010.
24. Mohr DC. The Stress and Mood Management Program for Individuals With Multiple Sclerosis: Workbook. New York: Oxford Press; 2010.
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD,Metz LM,McFarland HF, O'Connor PW, Sandberg-WollheimM, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-6.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurol 1983;33:1444-52.
27. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33;quiz 4-57.
28. Mohr DC, Boudewyn AC,Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942-9.
29. Verdier-Taillefer MH, Roullet E, Cesaro P, Alperovitch A. Validation of self-reported neurological disability in multiple sclerosis. Int J Epidemiol 1994;23:148-54.
30. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70.
31. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
32. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 2006;62: 123-46.
33. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A healthrelated quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
34. SAS Institute Inc. SAS Version 9.2. Cary, NC: SAS Institute Inc.; 2008.
35. Jose PE. ModGraph: A Computer Programme to Graphically Display Moderation. Excel ed. Wellington. New Zealand: Victoria University of Wellington; 2002.
36. Aiken LS, West SG. Multiple Regression: Testing and Interpreting Interactions. Newbury Park, CA: Sage Publications; 1991.
37. Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun 2006;20:27-36.
38. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;CD002002.